Stéphane Barete

Jan 8, 2025 | nature.com | Remy Duléry |Vincent Guiraud |Sylvain Choquet |Catherine Thieblemont |Emmanuel Bachy |Stéphane Barete | +3 more

AbstractThe risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018.